C.H. Boehringer Sohn AG & Co. KG group: subsidiaries and structure
Kommanditgesellschaft (KG) · Ingelheim am Rhein, Germany · LEI 529900P5FAANZASUYL28
41subsidiaries
16countries
41held directly
1lapsed LEIs
18links on accounts older than 24 months
1ISINs of subsidiaries
Summary
C.H. Boehringer Sohn AG & Co. KG is the ultimate parent of 41 subsidiaries with LEIs in 16 countries, as reported to GLEIF. 41 are held directly. The largest numbers are in Germany (18), in Austria (4) and in Switzerland (2). 1 of the subsidiaries has a lapsed LEI, and 18 links rest on accounts older than 24 months. GLEIF's ISIN mapping lists 0 ISINs for the parent and 1 ISIN for its subsidiaries.
Written from GLEIF data using fixed, reviewed sentence templates.
Subsidiaries by country
and 1 more
Data-quality notes (AssetCensus analysis)
No group-level data-quality notes in this data release.
18 subsidiaries have data-quality notes; they are listed on each company page.
Group structure
Indentation shows the direct parent reported to GLEIF.
Boehringer Ingelheim Pty Ltd Australia
Boehringer Ingelheim SComm Belgium
AMAL THERAPEUTICS SA Switzerland
T3 Pharmaceuticals AG Switzerland
Boehringer Ingelheim Europe GmbH Germany
Boehringer Ingelheim GmbH Germany
Boehringer Ingelheim Invest GmbH Germany
BOEHRINGER INGELHEIM DANMARK A/S Denmark
BOEHRINGER INGELHEIM ANIMAL HEALTH UK LIMITED United Kingdom
BOEHRINGER INGELHEIM LIMITED United Kingdom
BIDACHEM S.P.A. Italy
BOEHRINGER INGELHEIM N Z LIMITED New Zealand
Boehringer Ingelheim USA Corporation United States
Subsidiaries
| Company | Country | City | LEI | Accounts year | Notes |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharma Gesellschaft m.b.H. | Austria | Wien | 529900NHZEI01N3LYB33 | 2024 | |
| Boehringer Ingelheim RCV GmbH & Co KG | Austria | Wien | 529900WGDQUZBNJOLD52 | 2023 | > 24 months |
| Boehringer Ingelheim RCV Holding GmbH | Austria | Wien | 529900TP3LREB5U8EK61 | 2024 | |
| Forschungsinstitut für molekulare Pathologie Gesellschaft m.b.H. | Austria | Wien | 529900XIA762B58MYP48 | 2024 | |
| Boehringer Ingelheim Pty Ltd | Australia | North Ryde | 529900UG193CFEDVWX57 | 2023 | > 24 months |
| Boehringer Ingelheim SComm | Belgium | Elsene | 529900SKMCRMWF5BA426 | 2024 | |
| AMAL THERAPEUTICS SA | Switzerland | Genève | 52990091QOK2WBQB9Q20 | 2024 | |
| T3 Pharmaceuticals AG | Switzerland | Allschwil | 5299007PVTWSJ7OO3F95 | 2024 | |
| Boehringer Ingelheim Animal Health International GmbH | Germany | Ingelheim am Rhein | 529900MQK0OTRJOPUS81 | 2023 | > 24 months |
| Boehringer Ingelheim Animal Health Japan Holding GmbH | Germany | Ingelheim am Rhein | 529900U5OPY9L9FPUT06 | 2024 | |
| Boehringer Ingelheim Animal Health Participations GmbH | Germany | Ingelheim am Rhein | 529900SEAMD5W7ON9N16 | 2024 | |
| Boehringer Ingelheim Auslandsbeteiligungs GmbH | Germany | Ingelheim am Rhein | 529900ORCA4PGYL3WV90 | 2024 | |
| Boehringer Ingelheim Biopharmaceuticals GmbH | Germany | Ingelheim am Rhein | 52990023HHM6EZ0SYR34 | 2023 | > 24 months |
| Boehringer Ingelheim Corporate Center GmbH | Germany | Ingelheim am Rhein | 529900ZRSR0LJ3Q4DH04 | 2024 | |
| Boehringer Ingelheim Europe GmbH | Germany | Ingelheim am Rhein | 529900PUK2W10R64SZ68 | 2024 | |
| Boehringer Ingelheim GmbH | Germany | Ingelheim am Rhein | 529900SB4QTWSTSUIB39 | 2024 | |
| Boehringer Ingelheim International GmbH | Germany | Ingelheim am Rhein | 529900UYZPE4QQMRRE87 | 2024 | |
| Boehringer Ingelheim Invest GmbH | Germany | Ingelheim am Rhein | 529900J58Y1L9Q2R7T53 | 2024 | |
| Boehringer Ingelheim microParts GmbH | Germany | Dortmund | 5299007PH639WJXYQY39 | 2023 | > 24 months |
| Boehringer Ingelheim Middle East & Africa GmbH | Germany | Ingelheim am Rhein | 529900EZM0GN9OFSZO32 | 2024 | |
| Boehringer Ingelheim Pharma GmbH & Co. KG | Germany | Ingelheim am Rhein | 5299001JXIQ2V7N0ZD85 | 2024 | |
| Boehringer Ingelheim R&D Beteiligungs GmbH | Germany | Ingelheim am Rhein | 529900UQ5DB7A8NI6P20 | 2023 | > 24 months |
| Boehringer Ingelheim Secura Versicherungsvermittlungs GmbH | Germany | Ingelheim am Rhein | 5299009GK2QEALXHDS17 | 2024 | |
| Boehringer Ingelheim Venture Fund GmbH | Germany | Ingelheim am Rhein | 529900NUBLYH7ZS6N833 | 2023 | > 24 months |
| Boehringer Ingelheim Vetmedica Gesellschaft mit beschränkter Haftung | Germany | Ingelheim am Rhein | 5299005AHUEPP5HT2238 | 2023 | > 24 months |
| Boehringer lngelheim Therapeutics GmbH | Germany | Ochsenhausen | 391200OM7ZQLVZV6LJ42 | 2023 | > 24 months |
| Boehringer Ingelheim Animal Health Denmark A/S | Denmark | København S | 5493004VR3BEXP3HDG37 | 2024 | |
| BOEHRINGER INGELHEIM DANMARK A/S | Denmark | København S | 5299003YUGE7RLAPRS83 | 2023 | > 24 months |
| AGC PHARMA CHEMICALS EUROPE S.L. | Spain | Malgrat de Mar (Barcelona) | 529900C4WABB6Z4IH613 | 2019 | lapsed > 24 months |
| BOEHRINGER INGELHEIM ESPAÑA SA | Spain | SANT CUGAT DEL VALLÈS | 529900CCGQDEGVIQ5F77 | 2023 | > 24 months |
| Boehringer Ingelheim Animal Healts France | France | Lyon | 9695002CHM6WL9VX4K41 | 2023 | > 24 months |
| BOEHRINGER INGELHEIM ANIMAL HEALTH UK LIMITED | United Kingdom | Bracknell | 549300OIV51XASA1LT38 | 2024 | |
| BOEHRINGER INGELHEIM LIMITED | United Kingdom | Bracknell | 529900Z1BEMSZS73LN65 | 2023 | > 24 months |
| Μονοπρόσωπη Ανώνυμος Εταιρεία Παραγωγής Χημικών και Φαρμακευτικών Προϊόντων BOEHRINGER INGELHEIM ΕΛΛΑΣ ΜΟΝΟΠΡΟΣΩΠΗ Α.E. | Greece | Kallithea | 529900M2IKR7FONJ5048 | 2024 | |
| Boehringer Ingelheim Venture Fund Asia Limited | Hong Kong | Central Hong Kong | 5299000DCDFD8KQS3R46 | 2024 | |
| Boehringer Ingelheim India Private Limited | India | Mumbai | 5299007CWFCKHPNNVB87 | 2024 | |
| BIDACHEM S.P.A. | Italy | Fornovo San Giovanni | 5299006LCIO1TCO31H95 | 2023 | > 24 months |
| BOEHRINGER INGELHEIM MEXICO SA DE CV | Mexico | Xochimilco | 529900WJ39UB9DBU3220 | 2023 | > 24 months |
| Boehringer Ingelheim Promeco S.A. de C.V. | Mexico | Xochimilco | 529900HD97DI6LXV5A66 | 2024 | |
| BOEHRINGER INGELHEIM N Z LIMITED | New Zealand | Mount Wellington | 5299001NIRDJO24MWD45 | 2023 | > 24 months |
| Boehringer Ingelheim USA Corporation | United States | Wilmington | 529900CYZRW5B1JWEN34 | 2023 | > 24 months |